Gene therapy injected in one eye can travel to the other eye
By Clare Wilson,
New Scientist
| 12. 09. 2020
A gene therapy for a rare form of blindness seems to work well – but the genes injected into one eye have been found to travel to the untreated eye. The discovery has implications for safety, as well as for how the therapy’s effectiveness is measured, because such trials usually compare the treated eye’s vision with that of the untreated eye.
The experimental therapy is for a condition called Leber’s hereditary optic neuropathy, which usually affects young men and leads to progressive sight loss. It is caused by a mutation in one of the genes inside mitochondria, the energy-producing structures inside cells. This kills off cells of the retina, the patch of tissue at the back of the eye that turns light into electrical signals.
The gene therapy involves injecting a harmless virus containing the gene into the eye, where it is taken up by retinal cells. These start making the protein encoded by this gene, which passes into their mitochondria and helps preserve their remaining retina.
Eye disorders are a popular target for gene therapies, because they can...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...